<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00359229</url>
  </required_header>
  <id_info>
    <org_study_id>ZOLPI_L_01540</org_study_id>
    <nct_id>NCT00359229</nct_id>
  </id_info>
  <brief_title>Stilnox Treatment in Elderly Patients With Insomnia</brief_title>
  <acronym>STEP</acronym>
  <official_title>A Multicentre Prospective, Open Label ,3 Weeks Phase IV Study to Evaluate the Efficacy and Safety in Elder Patients With Insomnia in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary objective:

      1. To evaluate the efficacy of Zolpidem 5mg for 1 week in elderly patients with insomnia in
      China

      Secondary objectives:

        1. To evaluate the safety of Zolpidem 5mg for 3 weeks in elderly patients with insomnia in
           China.

        2. To evaluate the efficacy of Zolpidem 5mg for 3 weeks in elderly patients with insomnia
           in China
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pittsburgh Sleep Quality Index (PSQI) score</measure>
    <time_frame>At 1 week versus baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pittsburgh Sleep Quality Index score</measure>
    <time_frame>At 3 weeks versus baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject sleeping efficacy variable</measure>
    <time_frame>At 1 week and 3 weeks versus baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Depression Rating Scale (HAMD) and Hamilton Anxiety Rating Scale (HAMA) score</measure>
    <time_frame>At 3 weeks versus baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AE) and Serious adverse events (SAE) reports</measure>
    <time_frame>Throughout the study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General Lab tests including hepatic and renal function</measure>
    <time_frame>At 3 weeks versus baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>At 1 week and 3 weeks versus baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">115</enrollment>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zolpidem</intervention_name>
    <description>Administration of Zolpidem 5mg</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary out-patient insomniac patient defined by DSM-IV criteria

          -  Insomnia history lasted at least 3 months , this history must include a self-reported
             usual sleep latency of 30 minutes or more and either 3 or more awakenings per night on
             average or a usual total sleep time of â‰¤6.5 hours

        Exclusion Criteria:

          -  Usage of hypnotics within the previous 1-3 weeks before inclusion depending on the
             half-life of the hypnotics that would affect the study effect

          -  Concomitant usage of other hypnotics (benzodiazepines and Non-benzodiazepines) during
             the course if the study.

          -  Concomitant usage of the following Central Nervous System active medicine :
             antipsychotics , antidepressants ,anxiolytics, lithium and other psychotropic drugs.

          -  The score of Hamilton Depression Rating Scale (HAMD-24 ) more than 17.

          -  The score of Hamilton Anxiety Rating Scale (HAMA-14 ) more than 14.

          -  Patients having known hypersensitivity to Stilnox or any of the ingredients in the
             products

          -  Patient with severe respiratory insufficiency

          -  Patients suffering from sleep apnoea syndrome

          -  Patients with known severe hepatic (risk of encephalopathy) and /or renal
             insufficiency, or other severe organ diseases

          -  Patients suffering from severe myasthenia gravis

          -  Patients with the previous history of drug abuse, drug dependence and drug addiction

          -  Any other disease state or major psychiatric condition that might affect study result

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Jolain</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <removed_countries>
    <country>China</country>
  </removed_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2006</study_first_submitted>
  <study_first_submitted_qc>July 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2006</study_first_posted>
  <last_update_submitted>September 14, 2009</last_update_submitted>
  <last_update_submitted_qc>September 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zolpidem</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

